Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
about
Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma.Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.
P2860
Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Pharmacokinetics, Safety, and ...... Studies in Healthy Volunteers.
@ast
Pharmacokinetics, Safety, and ...... Studies in Healthy Volunteers.
@en
Pharmacokinetics, Safety, and ...... Studies in Healthy Volunteers.
@nl
type
label
Pharmacokinetics, Safety, and ...... Studies in Healthy Volunteers.
@ast
Pharmacokinetics, Safety, and ...... Studies in Healthy Volunteers.
@en
Pharmacokinetics, Safety, and ...... Studies in Healthy Volunteers.
@nl
prefLabel
Pharmacokinetics, Safety, and ...... Studies in Healthy Volunteers.
@ast
Pharmacokinetics, Safety, and ...... Studies in Healthy Volunteers.
@en
Pharmacokinetics, Safety, and ...... Studies in Healthy Volunteers.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics, Safety, and ...... Studies in Healthy Volunteers.
@en
P2093
David Sandham
Gerald Dubois
Lien Gheyle
Markus Weiss
Michael Larbig
Paul Goldsmith
Srikanth Neelakantham
Veit J Erpenbeck
Walid Elbast
P2860
P304
P356
10.1002/CPDD.244
P577
2016-03-28T00:00:00Z